A

Formulation (n=4)	Size	PDI	Zeta	Encapsulation efficiency (%)
Microparticle encapsulated tumor lysate (MP TL)	1.84 ± 0.50	0.41 ± 0.17	0.61 ± 3.18	74.9 ± 7.6

B



Supplementary Figure 1 (A) Characterization of A20 lysate encapsulated PLGA microparticle formulation (described as MP TL; Size- µm, Zeta-mV) and (B) Cumulative release of A20 lysate protein from PLGA MP (n=4). Data represent Mean ± S.D.



Supplementary Figure 2. (A) IFN-γ secreting CD8+ T cells percentage following re-stimulation of splenocytes with A20 tumor lysate ex vivo. Percentage of (B) NK cells, (C) MDSCs, and (D) Tregs in splenocytes. Naïve Balb/C mice were first injected with a lethal dose of A20 cells ($2x10^5$ cells/mice, IP) followed by 3 immunizations at days 8, 10, 14 with various tumor lysate formulations (100 μg lysate protein per mice, SC) and survival was tracked upto 56 days. At day 56, splenocytes were analyzed for IFN-γ secreting CD8+ T cells (after restimulation with A20 tumor lysate in vitro for 72 hrs) and various immune cell populations by flow cytometry. *P<0.05, **P<0.01, ***P<0.001; ****P<0.0001; One way ANOVA with Tukey multiple comparison test.